Cart
sales@molnova.com
BIBO 3304
CAS No. 191868-14-1
BIBO 3304( BIBO3304 )
Catalog No. M13008 CAS No. 191868-14-1
BIBO 3304 is a potent, selective, nonpeptide neuropeptide Y Y1 receptor antagonist with IC50 of 0.38 and 0.72 nM for human and the rat Y1 receptor, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 133 | In Stock |
|
| 5MG | 210 | In Stock |
|
| 10MG | 371 | In Stock |
|
| 25MG | 617 | In Stock |
|
| 50MG | 879 | In Stock |
|
| 100MG | 1188 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBIBO 3304
-
NoteResearch use only, not for human use.
-
Brief DescriptionBIBO 3304 is a potent, selective, nonpeptide neuropeptide Y Y1 receptor antagonist with IC50 of 0.38 and 0.72 nM for human and the rat Y1 receptor, respectively.
-
DescriptionBIBO 3304 is a potent, selective, nonpeptide neuropeptide Y Y1 receptor antagonist with IC50 of 0.38 and 0.72 nM for human and the rat Y1 receptor, respectively; shows low affinity for the human Y2 receptor, human and rat Y4 receptor, human and rat Y5 receptor (IC50>1,000 nM); inhibits the feeding response induced by 1 mg NPY in mice, also completely abolishes PYY-induced inhibition of insulin release in vivo.Obesity Discontinued(In Vivo):BIBO3304 TFA (30 μg; bilateral paraventricular nucleus injection) attenuates the hyperphagia following fasting.BIBO3304 TFA (15-60 μg) dose-dependently inhibits the feeding reponse mediated by 1 μg NPY.BIBO3304 TFA (0.5 μM; p.o.) significantly increases serum insulin levels.
-
In Vitro——
-
In VivoBIBO3304 TFA (30 μg; bilateral paraventricular nucleus injection) attenuates the hyperphagia following fasting.BIBO3304 TFA (15-60 μg) dose-dependently inhibits the feeding reponse mediated by 1 μg NPY.BIBO3304 TFA (0.5?μM; p.o.) significantly increases serum insulin levels. Animal Model:Adult male Chbb:Thom rats weighing between 300 and 340 g Dosage:30 μg Administration:bilateral paraventricular nucleus injection Result:Attenuated the hyperphagia following fasting, especially during the first 2 h of refeeding.Animal Model:7-week-old C57BL/6JAusb mice Dosage:0.5?μM Administration:p.o.Result:Significantly increased serum insulin levels.
-
SynonymsBIBO3304
-
PathwayGPCR/G Protein
-
TargetNeuropeptide Y Receptor
-
RecptorNeuropeptide Y Receptor
-
Research AreaMetabolic Disease
-
IndicationObesity
Chemical Information
-
CAS Number191868-14-1
-
Formula Weight643.668
-
Molecular FormulaC31H36F3N7O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (155.36 mM)
-
SMILESC1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)NC(CCCN=C(N)N)C(=O)NCC3=CC=C(C=C3)CNC(=O)N
-
Chemical Name(R)-2-(2,2-diphenylacetamido)-5-guanidino-N-(4-(ureidomethyl)benzyl)pentanamide 2,2,2-trifluoroacetate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
GR 231118
Potent neuropeptide Y (NPY) Y1 receptor antagonist (pA2 = 10 and 10.5 at rY1 and hY1, receptors respectively). Also a potent and selective NPY Y4 receptor agonist (pEC50 values are 6.0, 8.6 and 6.1 for rY2, hY4 and rY5 receptors respectively). Suppresses food intake in rats in vivo. Also has affinity for neuropeptide FF (NPFF) receptors in vitro (Ki = 43-73 nM).
-
Galnon
Galnon is a galanin receptor agonist, improves intrinsic cortical bone tissue propertiesGalnon has been characterized to inhibit seizures, decrease feeding behaviour, diminish physical signs of opiate withdrawal and to alleviate heat-hyperalgesic response to partial sciatic nerve injury.
-
[cPP1-7,NPY19-23,Ala...
Potent, selective peptide agonist for the neuropeptide Y Y5 receptor (IC50 values for inhibition of NPY binding to human Y5, Y1, Y2 and Y4 receptors are 0.24, 530, > 500, and 51 nM respectively, Ki at Y5 = 0.1 - 0.15 nM). Stimulates food intake in vivo.
